Influenza Vaccine: Clinical Trials

30 trials for Influenza Vaccine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 6 unknown, 3 active not recruiting, 1 not yet recruiting. 7 Not applicable, 6 Phase 4, 4 Phase 1, 3 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable7Completed 6, Not yet recruiting 1
Phase 46Completed 3, Unknown 2, Active not recruiting 1
Phase 14Active not recruiting 2, Completed 2
Phase 23Completed 3
Phase 32Completed 1, Unknown 1

Follow Influenza Vaccine: new trials by email Literature Review of Influenza Vaccine trials Research Report on Influenza Vaccine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine
Phase 1Active not recruitingAb&B Bio-tech Co., Ltd.JS802025-11-132026-02-19
Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
Quadrivalent Subunit Influenza Vaccine (Adjuvant), MF59, 0.9% sodium chloride injection (normal saline) - Influenza, Influenza Vaccine
Phase 1Active not recruitingAb&B Bio-tech Co., Ltd.JS802025-11-132026-02-19
Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers in China
Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot, Phase 2: motivational Interviewing - Influenza Vaccine, Healthcare Workers
Not applicableNot yet recruitingCenters for Disease Control and Prevention, China40502025-09-012025-09-11
Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China
quadrivalent subunit influenza vaccine - Influenza Vaccine
Phase 4CompletedAb&B Bio-tech Co., Ltd.JS31052024-11-152026-07-20
Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
Patient letter and clinician communication - COVID-19 Immunisation, Influenza Vaccine
Not applicableCompletedMayo Clinic1141652024-10-212025-08-05
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
Influenza vaccine - Influenza Vaccine, Immunocompromised Patients
CompletedInsel Gruppe AG, University Hospital Bern1472024-10-152025-03-26
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
Varicella vaccine+TIV, Varicella vaccine, TIV - Varicella, Influenza Vaccine
Phase 4CompletedSinovac (Dalian) Vaccine Technology Co., Ltd.8992024-09-212025-05-23
Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older
quadrivalent subunit influenza vaccine - Influenza Vaccine
CompletedAb&B Bio-tech Co., Ltd.JS428812023-10-302026-01-12
Cost-effectiveness of the Influenza Vaccination
Quadrivalent Influenza Vaccine - Influenza Vaccine, Cost-Effectiveness
Phase 4UnknownInternational Centre for Diarrhoeal Disease Research, Bangladesh25672022-09-292023-08-18
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3) - Aging, Influenza Vaccine
Phase 4Active not recruitingThe Jackson Laboratory752022-08-312026-08-03
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo - Influenza Vaccine
Phase 1CompletedFluGen Inc3032022-06-142022-11-14
Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination
Food Supplement, Placebo - Influenza Vaccine
Not applicableCompletedAB Biotics, SA1402021-10-262022-07-26
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
Sing2016 M2SR H3N2 influenza vaccine, Placebo - Influenza Vaccine
Phase 1CompletedFluGen Inc1222021-06-302023-06-15
Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients
Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) - ESRD, Influenza Vaccine
Phase 4UnknownMahidol University1752021-03-012021-11-03
Influenza 2020/2021
Appeals - Influenza Vaccine
Not applicableCompletedUniversity of Warwick2002020-09-212020-09-25
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine - Non Small Cell Lung Cancer, Influenza Vaccine
UnknownShanghai Pulmonary Hospital, Shanghai, China1602020-06-012020-04-21
Influenza Vaccine in Children With Asthma
Asthma in Children, Influenza Vaccine
UnknownCentral Hospital, Nancy, France5002019-11-042019-12-17
Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
Flu Vaccine - Influenza Vaccine, Cost-Benefit Analysis
CompletedFondazione Policlinico Universitario Agostino Gemelli IRCCS54832017-10-162024-03-12
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
GC3110A, GCFLU Pre-filled syringe inj. - Influenza Vaccine
Phase 3UnknownGreen Cross Corporation2602017-09-302017-09-18
Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial
Influenza Vaccine - Influenza Vaccine, Immune Response
UnknownTan Tock Seng Hospital2402017-05-312018-01-16

Showing 20 of 30. Sign in to see all of them.

Narrower conditions

Influenza, Human (30)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Chickenpox (1)  ·  Diabetes Mellitus (1)  ·  HIV Infections (1)  ·  Inflammatory Bowel Diseases (1)  ·  Kidney Failure, Chronic (1)  ·  Metabolic Diseases (1)  ·  Papillomavirus Infections (1)  ·  Sarcoidosis (1)  ·  Vitamin D Deficiency (1)  ·  Whooping Cough (1)

Broader conditions

Infections (30)  ·  Orthomyxoviridae Infections (30)  ·  RNA Virus Infections (30)  ·  Respiratory Tract Diseases (30)  ·  Respiratory Tract Infections (30)  ·  Virus Diseases (30)  ·  Urogenital Diseases (3)  ·  Communicable Diseases (2)  ·  DNA Virus Infections (2)  ·  Disease Attributes (2)  ·  Genital Diseases (2)  ·  Immune System Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Sexually Transmitted Diseases (2)

Interventions

Influenza Vaccines (10)  ·  Adjuvants, Pharmaceutic (2)  ·  MF59 oil emulsion (2)  ·  Saline Solution (2)  ·  Sodium Chloride (2)  ·  vaxigrip (2)  ·  Antigens, Surface (1)  ·  Blood Specimen Collection (1)  ·  Chickenpox Vaccine (1)  ·  Dietary Supplements (1)  ·  FluMist (1)  ·  Imiquimod (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Probiotics (1)  ·  fluad vaccine (1)

Sponsors

Ab&B Bio-tech Co., Ltd.JS (4)  ·  FluGen Inc (2)  ·  University of Alberta (2)  ·  AB Biotics, SA (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Boston Children's Hospital (1)  ·  Centers for Disease Control and Prevention, China (1)  ·  Central Hospital, Nancy, France (1)  ·  Duke University (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Green Cross Corporation (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  International Centre for Diarrhoeal Disease Research, Bangladesh (1)  ·  Mahidol University (1)  ·  Mayo Clinic (1)

Countries

United States (7)  ·  China (6)  ·  Canada (3)  ·  Switzerland (3)  ·  France (2)  ·  Bangladesh (1)  ·  Italy (1)  ·  Russia (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)  ·  Thailand (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Pamuk Bilsel (2)  ·  Yeqing Tong, Doctor (2)  ·  Christine Thurnheer, PD, MD (1)  ·  Claire Le Jeunne, MD, PhD (1)  ·  David W Scheifele, MD (1)  ·  Deepali Kumar (1)  ·  Deepali Kumar, Msc, FRCPC (1)  ·  Geeta Swamy, MD (1)  ·  George Kuchel, MD, FRCP (1)  ·  Lila J. Rutten, PhD (1)  ·  Maria Allende, M.D. (1)  ·  Oleg I Kiselev, Ph.D. (1)  ·  Oriol Manuel, MD (1)

Results publications

PMID 10439494, PMID 10471173, PMID 15195237, PMID 16372666, PMID 17908277, PMID 18425905, PMID 20532100, PMID 21288852, PMID 21377898, PMID 21806398, PMID 21820477, PMID 22271960, PMID 22872731, PMID 23042206, PMID 23210147, PMID 23581957, PMID 23732900, PMID 23830973, PMID 23974637, PMID 24055351, PMID 24750586, PMID 24791735, PMID 25902573, PMID 26336905, PMID 26842617, PMID 27646030, PMID 27746226, PMID 27980374, PMID 28506297, PMID 28623028, PMID 28867508, PMID 28923425, PMID 29024434, PMID 29063064, PMID 29100706, PMID 29197154, PMID 29197174, PMID 29232882, PMID 29388197, PMID 29416317, PMID 30471956, PMID 30715348, PMID 30793097, PMID 32066407, PMID 33272702, PMID 33578007, PMID 33586871, PMID 33736920, PMID 33990365, PMID 34451991

NIH funding

2016 (1), U01AI165452 (1)